



Conversion of convertibles in a nominal amount of SEK 37,519,480 to 833,766,222 Class B shares

On 24 February 2026, Episurf Medical AB (publ) ("**Episurf**") issued convertibles in an aggregated nominal amount of SEK 87,380,906 as part of the consideration to be paid for the acquisition of Frusipe Intressenter Target 1 AB. Convertibles in a nominal amount of SEK 37,519,480 have, as of the date of this press release, at the request from holders of convertibles, been converted into 833,766,222 Class B shares in Episurf at a conversion price of SEK 0.045 per share in accordance with the terms and conditions.

Through the conversion, the number of Class B shares and votes in Episurf increases by 833,766,222, corresponding to a dilution effect of approximately 12.03 per cent of the shares and the votes respectively. Through the conversion, the share capital increases by SEK 8,337,662.22.

For further details, please contact:

Jens Andersson, CEO, Episurf Medical

Tel: +46 (0) 768 55 67 02

Email: jens.andersson@episurf.com

The information was submitted for publication, through the agency of the contact person set out above, at 19:30 CEST on 22 June, 2026.

About Episurf Medical AB

Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The company's objective is to create value growth through the acquisition and management of Nordic properties. The company also has a medical technology business based on the individualised implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is located in Stockholm, Sweden.